Sanofi’s MS Candidate Tolebrutinib On Clinical Hold Following Liver Toxicities
But Studies Going Strong
The firm’s BTK inhibitor tolebrutinib has been put on clinical hold by the US FDA following liver injuries, but advanced trials should continue as normal since most patients have passed the 60-day mark.
You may also be interested in...
Cytokinetics has a lot riding on the upcoming Phase III readout for aficamten, and crunch time is coming for plenty of other groups, too.
The major’s BTK inhibitor candidate, remibrutinib, met the primary and secondary endpoints of two Phase III trials in chronic spontaneous urticaria, with unproblematic liver function results so far, suggesting it may avoid pitfalls faced by rivals.
The German major’s healthcare sales saw organic double-digit growth in the second quarter but worries about the viability of its BTK inhibitor approach in multiple sclerosis as well as new competition for cancer drug Bavencio render future prospects less certain.